Iasi

• A phase III, randomised, double-blind, multicentre study comparing the efficacy, safety, and immunogenicity of proposed tocilizumab biosimil … Not authorised
  2022-501361-44-00 5 Adult patients of either gender with active moderate to severe rheumat
• REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis. Pending
  2024-519298-21-00 5 Cancer-Associated Thrombosis (CAT).
• An Open-Label Study of ML-007C-MA in Adults with Alzheimer’s Disease Psychosis Pending
  2025-521757-16-00 4 Hallucinations and Delusions Associated with Alzheimer’s Disease Psych
• IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after … Pending
  2025-521908-22-00 10 EGFR-mutated Non-small Cell Lung Cancer
• A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (13 to 17 years of age) Pending
  2025-523711-11-00 5 Schizophrenia
• Phase 3 Evaluation of KarXT and KarXT+KarX-EC in Schizophrenia and Autism-Related Irritability in Youth, respectively. Pending
  2025-524062-16-00 5 Schizophrenia and Autism Spectrum Disorder (ASD)
• A phase 3 study of orelabrutinib in combination with rituximab plus bendamustine (BR) compared with BR in subjects with treatment-naїve mant … Pending
  2025-524241-27-00 5 Treatment-naїve mantle cell lymphoma (MCL)
• BETRI-Prospective: Asthma control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 µg]) vs Single Inhaler ICS/LABA (200/ … Pending
  2025-524289-56-00 6 Asthma
• A randomized, balanced, two-treatment, two-sequence, single oral dose, two stage crossover adaptative bioequivalence study of Rifaximin 200 … Pending
  2025-525078-12-00 2 healthy subjects
• Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia Recruiting
  2025-524810-28-00 5 2026-07-02 Acute Promyelocytic Leukemia
• A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Recruiting
  2025-523576-23-00 5 2026-06-12 Unresectable Stage III non-small cell lung cancer without progression
• A Study of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50% Recruiting
  2025-523586-18-00 5 2026-06-11 Non-Small Cell Lung Cancer
• A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants with Platinum-Resistant (Part A) and Platinum-Sensitive (Part B … Recruiting
  2025-522255-25-00 5 2026-05-18 Fallopian Tube Neoplasms
• A Global Study Testing the New Drug Olverembatinib combined with chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Pos … Recruiting
  2024-511496-14-00 5 2026-05-14 Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic L
• Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML Recruiting
  2025-522279-27-00 5 2026-04-02 Newly Diagnosed AML with an NPM1 mutation
• Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus. Recruiting
  2025-522729-36-00 7 2026-03-11 Chronic Hepatitis Delta.
• Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in … Recruiting
  2025-521627-78-00 5 2026-01-28 Neoplasms, Lung
• A Study of Navlimetostat (BMS-986504) in Combination with Pembrolizumab Plus Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy … Recruiting
  2025-521511-40-00 10 2025-11-18 metastatic non-small cell lung cancer
• A Phase 3 Single-arm Study of UGN-104 for the Treatment of LG-UTUC Recruiting
  2024-519343-15-00 5 2025-10-08 Low-grade Upper Tract Urothelial Cancer
• A Study to Learn About the Study Medicine Called Sigvotatug Vedotin in People with Locally Advanced, Unresectable, or Metastatic Non-Small C … Recruiting
  2024-517968-36-00 5 2025-07-08 non-small cell lung cancer
• An Extension Study to Evaluate Safety, Efficacy, and Durability of Response to ESK-001 for Moderate to Severe Plaque Psoriasis (ONWARD3) Recruiting
  2024-511166-36-00 5 2025-06-13 Moderate to Severe Plaque Psoriasis
• A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-022) Recruiting
  2023-508015-23-00 5 2025-04-11 Ovarian cancer recurrent
• Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C … Recruiting
  2024-515445-42-00 5 2025-03-24 Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
• A phase 3 multi-center trial to evaluate the efficacy and safety of tralokinumab in combination with topical corticosteroids in children (ag … Recruiting
  2023-503630-44-00 10 2024-11-20 Treatment of moderate-to-severe Atopic dermatitis

Showing 1–24 of 144 trials